Silence Therapeutics launches $150 million ADS follow-on offering

Silence Therapeutics has launched a $150 million underwritten public offering of American depositary shares (ADS) in the U.S. Each ADS represents three ordinary shares, and underwriters have a 30-day option to purchase up to 15% more. Jefferies, Morgan Stanley, Cantor, and William Blair are serving as joint book-running managers for this follow-on offering.

Silence Therapeutics launched an underwritten public offering of about USD 150 million of American depositary shares in the U.S. * Each ADS represents three ordinary shares; underwriters hold a 30-day option to buy up to 15% more ADSs. * Jefferies, Morgan Stanley, Cantor, William Blair named joint book-running managers. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silence Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202608101601BIZWIRE_USPR_____20260810_BW617219) on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)